DE69833105D1 - Verfahren zur feststellung der anwesenheit mutierten brca proteins - Google Patents

Verfahren zur feststellung der anwesenheit mutierten brca proteins

Info

Publication number
DE69833105D1
DE69833105D1 DE69833105T DE69833105T DE69833105D1 DE 69833105 D1 DE69833105 D1 DE 69833105D1 DE 69833105 T DE69833105 T DE 69833105T DE 69833105 T DE69833105 T DE 69833105T DE 69833105 D1 DE69833105 D1 DE 69833105D1
Authority
DE
Germany
Prior art keywords
determining
relates
protein
proteins
mutated brca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833105T
Other languages
English (en)
Inventor
A Adams
J Byrne
M Cohn
T Reece
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baystate Medical Center Inc
Original Assignee
Baystate Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baystate Medical Center Inc filed Critical Baystate Medical Center Inc
Application granted granted Critical
Publication of DE69833105D1 publication Critical patent/DE69833105D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
DE69833105T 1997-03-24 1998-03-23 Verfahren zur feststellung der anwesenheit mutierten brca proteins Expired - Lifetime DE69833105D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4233797P 1997-03-24 1997-03-24
PCT/US1998/005618 WO1998043092A1 (en) 1997-03-24 1998-03-23 Method for determining the presence of mutated brca protein

Publications (1)

Publication Number Publication Date
DE69833105D1 true DE69833105D1 (de) 2006-03-30

Family

ID=21921326

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833105T Expired - Lifetime DE69833105D1 (de) 1997-03-24 1998-03-23 Verfahren zur feststellung der anwesenheit mutierten brca proteins

Country Status (7)

Country Link
US (1) US5965377A (de)
EP (1) EP0975973B1 (de)
AT (1) ATE315231T1 (de)
AU (1) AU6473598A (de)
CA (1) CA2284817C (de)
DE (1) DE69833105D1 (de)
WO (1) WO1998043092A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022184A1 (en) * 1996-02-12 2003-01-30 Oncormed. Inc. Coding sequences of the human BRCA1 gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
WO2001018542A2 (en) * 1999-09-03 2001-03-15 Millennium Pharmaceuticals, Inc. Identification, assessment, prevention, and therapy of ovarian cancer
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
WO2002046765A2 (en) * 2000-11-08 2002-06-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
KR100468466B1 (ko) * 2001-08-25 2005-01-27 주식회사 랩 지노믹스 유방암 및 난소암 진단에 유용한 ｂｒｃａ１, ｂｒｃａ２유전자 돌연변이 및 이를 이용한 검색 방법
MXPA05006193A (es) * 2002-12-11 2005-12-05 Ferrosan As Materiales basados en gelatina como hisopos.
CN102014973A (zh) 2008-02-29 2011-04-13 弗罗桑医疗设备公司 用于促进止血和/或伤口愈合的装置
WO2012071096A2 (en) 2010-09-03 2012-05-31 The Johns Hopkins University Arid1a and ppp2r1a mutations in cancer
EP2822474B1 (de) 2012-03-06 2018-05-02 Ferrosan Medical Devices A/S Druckbehälter mit einer blutstillenden paste
KR20150039130A (ko) 2012-05-25 2015-04-09 라보라토이레 에이치알에이 파르마 유방 종양의 예방 및 치료를 위한 울리프리스탈 아세테이트
BR112014030962A2 (pt) 2012-06-12 2017-06-27 Ferrosan Medical Devices As métodos para preparação e para reconstituição de uma composição seca adequada para uso em hemostase e cicatrização de feridas, e, kit hemostático
US9724078B2 (en) 2013-06-21 2017-08-08 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
EP3470094B1 (de) 2013-12-11 2020-07-22 Ferrosan Medical Devices A/S Trockenzusammensetzung mit extrusionsverstärker
WO2016058612A1 (en) 2014-10-13 2016-04-21 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
WO2016102446A1 (en) 2014-12-24 2016-06-30 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
WO2017005590A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
EP3697767A4 (de) 2017-10-16 2021-09-01 Dana Farber Cancer Institute, Inc. Verbindungen und verwendung zur behandlung von krebs
EP4321182A2 (de) 2018-05-09 2024-02-14 Ferrosan Medical Devices A/S Verfahren zur herstellung einer hämostatischen zusammensetzung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283190A (en) * 1989-07-31 1994-02-01 Traish Adbulmaged M Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use
US5252458A (en) * 1990-12-31 1993-10-12 Symex Corp. Method for visually detecting the presence of a virus in a clinical specimen
US5622829A (en) * 1993-12-08 1997-04-22 The Regents Of The University Of California Genetic markers for breast, ovarian, and prostatic cancer
JP2002503943A (ja) * 1994-08-12 2002-02-05 ミリアド・ジェネティックス・インコーポレイテッド １７ｑ−連鎖乳癌および卵巣癌感受性遺伝子におけるイン・ビボ突然変異および多形性
ES2154712T5 (es) * 1994-08-12 2009-12-14 The University Of Utah Research Foundation Metodo para diagnosticar la predisposicion al cancer de mama y de ovarios.
US5645995A (en) * 1996-04-12 1997-07-08 Baylor College Of Medicine Methods for diagnosing an increased risk for breast or ovarian cancer
US5905026A (en) * 1996-08-27 1999-05-18 Cornell Research Foundation, Inc. Method of detecting expression of and isolating the protein encoded by the BRCA1 gene

Also Published As

Publication number Publication date
WO1998043092A1 (en) 1998-10-01
EP0975973B1 (de) 2006-01-04
US5965377A (en) 1999-10-12
CA2284817C (en) 2003-08-19
ATE315231T1 (de) 2006-02-15
CA2284817A1 (en) 1998-10-01
EP0975973A1 (de) 2000-02-02
AU6473598A (en) 1998-10-20

Similar Documents

Publication Publication Date Title
DE69833105D1 (de) Verfahren zur feststellung der anwesenheit mutierten brca proteins
DE69519834D1 (de) Verfahren zum Nachweis von Prädisposition von Ovarial- und Brustkrebs
DE59903915D1 (de) Verfahren zur frühen diagnose von carcinomen
DK0961780T3 (da) Proteinmarkörer for lungecancer og anvendelse deraf
DE60041839D1 (de) Auto-Antikörper gegen Annexin-Proteine als Marker für Lungenkrebs
DE59710933D1 (de) Messanordnung zur optischen Bestimmung der totalen Hämoglobinkonzentration
HK1045561A1 (zh) 蛋白質的分離和分析
DE69521002T2 (de) Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
DE60129151D1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
HK1021229A1 (en) A in vitro method of determining the presence of aprotein in an isolated biological sample.
SE9500030D0 (sv) Method of determining metastatic potential of tumor cells
PT981644E (pt) Mutacao apc associada com o cancro colorectal familiar em judeus ashkenazi
DK0495910T3 (da) Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
DE69016858T2 (de) Verfahren und Reagenziensatz zur Bestimmung der funktionalen Aktivität von Protein S in menschlichem Plasma.
IL147486A0 (en) Methods and reagents for determining the prognosis of cancer patients by measuring bag proteins
HUP0303905A2 (hu) KIAA-nukleinsavak és -polipeptidek prosztatarák diagnosztizálására és gyógykezelésére alkalmas expressziós analízise
ATE320602T1 (de) Verfahren und testsatz zur evaluierung der metastasierungstendenz von tumoren
DE69839846D1 (de) Bestimmung der vorhandenen mengen an cyclin-abhängr bei krebspatienten
ATE253223T1 (de) Verfahren und materialien zur diagnose instabiler angina
DE69735676D1 (de) Proteinmarker für ösophaguskrebs
FR2761697B1 (fr) Methodes de detection d'interactions entre plusieurs proteines
Laszewski VARIATIONS IN CALCIUM SENSITIVITY, MAXIMUM SHORTENING VELOCITY AND PROTEIN COMPOSITION IN HISTOCHEMICALLY-TYPED MUSCLE FIBERS OF THE RAT.
DE29701030U1 (de) Vorrichtung zur Ermittlung der Abriebfestigkeit von flächenförmigen Kunststoffprüfkörpern
FR2790958B1 (fr) Detection dans un echantillon biologique de la proteine hsi, cette proteine etant associee a un cancer mammaire
IT9047780A0 (it) Metodo per la determinazione quantitativa di sequenze specifiche di dna mediante sonde non radioattive e relativo kit.

Legal Events

Date Code Title Description
8332 No legal effect for de